Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies

1st Edition

Peter Grunwald

Jenny Stanford Publishing
July 31, 2020 Forthcoming
Reference - 500 Pages
ISBN 9789814877138 - CAT# 369619
Series: Jenny Stanford Series on Biocatalysis

For Instructors Request Inspection Copy

was $249.95

USD$199.96

SAVE ~$49.99

Available for pre-order. Item will ship after July 31, 2020
Add to Wish List
FREE Standard Shipping!

Summary

This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, β-Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.

Instructors

We provide complimentary e-inspection copies of primary textbooks to instructors considering our books for course adoption.

Request an
e-inspection copy

Share this Title